PT - JOURNAL ARTICLE AU - A Godin AU - Y Xia AU - DL Buckeridge AU - S Mishra AU - D Douwes-Schultz AU - Y Shen AU - M Lavigne AU - M Drolet AU - AM Schmidt AU - M Brisson AU - M Maheu-Giroux TI - Importation of SARS-CoV-2 following the <em>“semaine de relâche”</em> and Québec’s COVID-19 burden - a mathematical modeling study AID - 10.1101/2020.07.20.20158451 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.20.20158451 4099 - http://medrxiv.org/content/early/2020/08/30/2020.07.20.20158451.short 4100 - http://medrxiv.org/content/early/2020/08/30/2020.07.20.20158451.full AB - Background The Canadian epidemics of COVID-19 exhibit distinct early trajectories, with Québec bearing a very high initial burden. The semaine de relâche, or March break, took place two weeks earlier in Québec as compared to the rest of Canada. This event may have played a role in the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We aimed to examine the role of case importation in the early transmission dynamics of SARS-CoV-2 in Québec.Methods Using detailed surveillance data, we developed and calibrated a deterministic SEIR-type compartmental model of SARS-CoV-2 transmission. We explored the impact of altering the number of imported cases on hospitalizations. Specifically, we investigated scenarios without case importation after March break, and as scenarios where cases were imported with the same frequency/timing as neighboring Ontario.Results A total of 1,544 and 1,150 returning travelers were laboratory-confirmed in Québec and Ontario, respectively (with symptoms onset before 2020-03-25). The cumulative number of hospitalizations could have been reduced by 55% (95%CrI: 51-59%) had no cases been imported after Québec’s March break. However, had Québec experienced Ontario’s number of imported cases, cumulative hospitalizations would have only been reduced by 12% (95%CrI: 8-16%).Interpretation Our results suggest that case importation played an important role in the early spread of COVID-19 in Québec. Yet, heavy importation of SARS-CoV-2 in early March could be insufficient to resolve interprovincial heterogeneities in cumulative hospitalisations. The importance of other factors-public health preparedness, responses, and capacity-should be investigated.Competing Interest StatementMM-G report contractual agreements with the Institut national de santé publique du Québec (INSPQ) and the Institut d'excellence en santé et en services sociaux (INESSS). In addition, MM-G discloses an investigator-sponsored research grant from Gilead Sciences Inc., and funding from both the World Health Organization and the Joint United Nations Programme on HIV/AIDS (UNAIDS), outside of the submitted work. DLB disclose a contractual agreement with INESSS and MB reports research funding from INSPQ.Funding StatementWe acknowledge financial support from the McGill Interdisciplinary Initiative in Infection and Immunity (MI4; to MM-G), with seed funding from the MUHC Foundation, and a Canadian Institutes of Health Research (CIHR) COVID-19 Rapid Research Grant (to SM). MM-G's research program is supported by a Canada Research Chair (Tier 2) in Population Health Modeling. SM's research program is supported by a Canada Research Chair (Tier 2) in Mathematical Modeling and Program Science.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for secondary analyses of provincial surveillance data was obtained from McGill University's Institutional Review Board. Secondary analyses of iPHIS data, via the Ontario COVID-19 Modelling Consensus Table, were conducted with approval from the University of Toronto Health Sciences' Research Ethics Board (protocol No. 39253).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPart of the data used in this article has not been released in the public domain yet. https://www.inspq.qc.ca/covid-19/donnees